{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T13:07:58Z","timestamp":1785157678424,"version":"3.55.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,10,3]]},"DOI":"10.7759\/cureus.70794","type":"journal-article","created":{"date-parts":[[2024,10,4]],"date-time":"2024-10-04T00:41:29Z","timestamp":1728002489000},"source":"Crossref","is-referenced-by-count":5,"title":["Linezolid-Induced Lactic Acidosis Presenting As Acute Cholecystitis: A Case Report and Systematic Review"],"prefix":"10.7759","author":[{"given":"Fahima","family":"Akter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Bozell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tyson","family":"Neumann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2016.1182154","article-title":"Risk factors associated with high linezolid trough plasma concentrations","volume":"17","author":"Morata L","year":"2016","unstructured":"Morata L, De la Calle C, G\u00f3mez-Cerquera JM, et al.. Risk factors associated with high linezolid trough plasma concentrations. Expert Opin Pharmacother. 2016, 17:1183-7. 10.1080\/14656566.2016.1182154","journal-title":"Expert Opin Pharmacother"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2006.08.030","article-title":"Linezolid for the treatment of adults with bone and joint infections","volume":"29","author":"Falagas ME","year":"2007","unstructured":"Falagas ME, Siempos II, Papagelopoulos PJ, Vardakas KZ. Linezolid for the treatment of adults with bone and joint infections. Int J Antimicrob Agents. 2007, 29:233-9. 10.1016\/j.ijantimicag.2006.08.030","journal-title":"Int J Antimicrob Agents"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-86-5-674_1","article-title":"Clinical and Biochemical Aspects of Lactic Acidosis","author":"Cohen RD","year":"1976","unstructured":"Cohen RD, Woods HF, Krebs HA. Clinical and Biochemical Aspects of Lactic Acidosis. Blackwell Scientific Publications, London; 1976. 10.7326\/0003-4819-86-5-674_1"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1056\/nejm200301023480123","article-title":"Linezolid-induced lactic acidosis","volume":"348","author":"Apodaca AA","year":"2003","unstructured":"Apodaca AA, Rakita RM. Linezolid-induced lactic acidosis. N Engl J Med. 2003, 348:86-7. 10.1056\/nejm200301023480123","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/S0163-4453(09)60009-8","article-title":"Linezolid: a review of safety and tolerability","volume":"59","author":"Vinh DC","year":"2009","unstructured":"Vinh DC, Rubinstein E. Linezolid: a review of safety and tolerability. J Infect. 2009, 59:59-74. 10.1016\/S0163-4453(09)60009-8","journal-title":"J Infect"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"10","author":"Page MJ","year":"2020","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2020, 10:89. 10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2013-201554","article-title":"The CARE guidelines: consensus-based clinical case reporting guideline development","volume":"2013","author":"Gagnier JJ","year":"2013","unstructured":"Gagnier JJ, Kienle G, Altman DG, Moher D, Sox H, Riley D. The CARE guidelines: consensus-based clinical case reporting guideline development. BMJ Case Rep. 2013, 2013:bcr2013201554. 10.1136\/bcr-2013-201554","journal-title":"BMJ Case Rep"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2012.09.016","article-title":"Testing a tool for assessing the risk of bias for nonrandomized studies showed moderate reliability and promising validity","volume":"66","author":"Kim SY","year":"2013","unstructured":"Kim SY, Park JE, Lee YJ, et al.. Testing a tool for assessing the risk of bias for nonrandomized studies showed moderate reliability and promising validity. J Clin Epidemiol. 2013, 66:408-14. 10.1016\/j.jclinepi.2012.09.016","journal-title":"J Clin Epidemiol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1592\/phco.27.8.1189","article-title":"Linezolid-associated peripheral and optic neuropathy, lactic acidosis, and serotonin syndrome","volume":"27","author":"Narita M","year":"2007","unstructured":"Narita M, Tsuji BT, Yu VL. Linezolid-associated peripheral and optic neuropathy, lactic acidosis, and serotonin syndrome. Pharmacotherapy. 2007, 27:1189-97. 10.1592\/phco.27.8.1189","journal-title":"Pharmacotherapy"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2014.06.017","article-title":"Early lactic acidosis associated with linezolid therapy in paediatric patients","volume":"44","author":"Ozkaya-Parlakay A","year":"2014","unstructured":"Ozkaya-Parlakay A, Kara A, Celik M, Ozsurekci Y, Karadag Oncel E, Ceyhan M, Cengiz AB. Early lactic acidosis associated with linezolid therapy in paediatric patients. Int J Antimicrob Agents. 2014, 44:334-6. 10.1016\/j.ijantimicag.2014.06.017","journal-title":"Int J Antimicrob Agents"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jiac.2020.07.018","article-title":"Severe linezolid-induced lactic acidosis in a child with acute lymphoblastic leukemia: a case report","volume":"26","author":"Smolka V","year":"2020","unstructured":"Smolka V, Rohanova M, Ludikova B, Novak Z, Zapalka M, Pospisilova D, Volejnikova J. Severe linezolid-induced lactic acidosis in a child with acute lymphoblastic leukemia: a case report. J Infect Chemother. 2020, 26:1316-18. 10.1016\/j.jiac.2020.07.018","journal-title":"J Infect Chemother"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0b013e3182186035","article-title":"Linezolid and lactic acidosis: a role for lactate monitoring with long-term linezolid use in children","volume":"30","author":"Su E","year":"2011","unstructured":"Su E, Crowley K, Carcillo JA, Michaels MG. Linezolid and lactic acidosis: a role for lactate monitoring with long-term linezolid use in children. Pediatr Infect Dis J. 2011, 30:804-6. 10.1097\/INF.0b013e3182186035","journal-title":"Pediatr Infect Dis J"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.604680","article-title":"Incidence and associated risk factors for lactic acidosis induced by linezolid therapy in a case-control study in patients older than 85 years","volume":"25","author":"Liu T","year":"2021","unstructured":"Liu T, Hu C, Wu J, et al.. Incidence and associated risk factors for lactic acidosis induced by linezolid therapy in a case-control study in patients older than 85 years. Front Med (Lausanne). 2021, 25:604680. 10.3389\/fmed.2021.604680","journal-title":"Front Med (Lausanne)"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-017-2377-1","article-title":"Comparative analysis of lactic acidosis induced by linezolid and vancomycin therapy using cohort and case-control studies of incidence and associated risk factors","volume":"74","author":"Mori N","year":"2018","unstructured":"Mori N, Kamimura Y, Kimura Y, Hirose S, Aoki Y, Bito S. Comparative analysis of lactic acidosis induced by linezolid and vancomycin therapy using cohort and case-control studies of incidence and associated risk factors. Eur J Clin Pharmacol. 2018, 74:405-11. 10.1007\/s00228-017-2377-1","journal-title":"Eur J Clin Pharmacol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2014.12.009","article-title":"Incidence and risk factors of linezolid-induced lactic acidosis","volume":"31","author":"Im JH","year":"2015","unstructured":"Im JH, Baek JH, Kwon HY, Lee JS. Incidence and risk factors of linezolid-induced lactic acidosis. Int J Infect Dis. 2015, 31:47-52. 10.1016\/j.ijid.2014.12.009","journal-title":"Int J Infect Dis"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1038\/nrneph.2010.20","article-title":"A case of lactic acidosis induced by linezolid","volume":"6","author":"Velez JC","year":"2010","unstructured":"Velez JC, Janech MG. A case of lactic acidosis induced by linezolid. Nat Rev Nephrol. 2010, 6:236-42. 10.1038\/nrneph.2010.20","journal-title":"Nat Rev Nephrol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02856-14","article-title":"Linezolid-induced lactic acidosis in two liver transplant patients with the mitochondrial DNA A2706G polymorphism","volume":"58","author":"Del Pozo JL","year":"2014","unstructured":"Del Pozo JL, Fern\u00e1ndez-Ros N, S\u00e1ez E, Herrero JI, Yuste JR, Banales JM. Linezolid-induced lactic acidosis in two liver transplant patients with the mitochondrial DNA A2706G polymorphism. Antimicrob Agents Chemother. 2014, 58:4227-9. 10.1128\/AAC.02856-14","journal-title":"Antimicrob Agents Chemother"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.11514","article-title":"Linezolid induced lactic acidosis: the side effect, clinician should be aware of","volume":"16","author":"Nightingale S","year":"2020","unstructured":"Nightingale S, Austin C, Agarwal KK, Patel M, Hossain M. Linezolid induced lactic acidosis: the side effect, clinician should be aware of. Cureus. 2020, 16:e11514. 10.7759\/cureus.11514","journal-title":"Cureus"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1080\/00365540410026022","article-title":"Linezolid use associated with lactic acidosis","volume":"37","author":"Kopterides P","year":"2005","unstructured":"Kopterides P, Papadomichelakis E, Armaganidis A. Linezolid use associated with lactic acidosis. Scand J Infect Dis. 2005, 37:153-4. 10.1080\/00365540410026022","journal-title":"Scand J Infect Dis"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2017.1335305","article-title":"Linezolid-induced lactic acidosis: the thin line between bacterial and mitochondrial ribosomes","volume":"16","author":"Santini A","year":"2017","unstructured":"Santini A, Ronchi D, Garbellini M, Piga D, Protti A. Linezolid-induced lactic acidosis: the thin line between bacterial and mitochondrial ribosomes. Expert Opin Drug Saf. 2017, 16:833-43. 10.1080\/14740338.2017.1335305","journal-title":"Expert Opin Drug Saf"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000012114","article-title":"The risk factors of linezolid-induced lactic acidosis: a case report and review","volume":"97","author":"Mao Y","year":"2018","unstructured":"Mao Y, Dai D, Jin H, Wang Y. The risk factors of linezolid-induced lactic acidosis: a case report and review. Medicine (Baltimore). 2018, 97:e12114. 10.1097\/MD.0000000000012114","journal-title":"Medicine (Baltimore)"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1111\/jcpt.13245","article-title":"Linezolid and the risk of lactic acidosis: data mining and analysis of the FDA Adverse Event Reporting System","volume":"45","author":"Dai Y","year":"2020","unstructured":"Dai Y, Wang Y, Zeng Y, Zhang C, Zhou Z, Shi D. Linezolid and the risk of lactic acidosis: data mining and analysis of the FDA Adverse Event Reporting System. J Clin Pharm Ther. 2020, 45:1422-6. 10.1111\/jcpt.13245","journal-title":"J Clin Pharm Ther"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.12659\/AJCR.911362","article-title":"Lactic acidosis and thrombocytopenia associated with linezolid therapy: a case report","volume":"19","author":"Xiao B","year":"2018","unstructured":"Xiao B, Deng P, Jin H, Wang H, Cao Y. Lactic acidosis and thrombocytopenia associated with linezolid therapy: a case report. Am J Case Rep. 2018, 19:1117-20. 10.12659\/AJCR.911362","journal-title":"Am J Case Rep"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1007\/s15010-007-6302-x","article-title":"Lactic acidosis after treatment with linezolid","volume":"35","author":"Wiener M","year":"2007","unstructured":"Wiener M, Guo Y, Patel G, Fries BC. Lactic acidosis after treatment with linezolid. Infection. 2007, 35:278-81. 10.1007\/s15010-007-6302-x","journal-title":"Infection"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1177\/0897190018782787","article-title":"A case of linezolid induced toxicity","volume":"33","author":"Tobias PE","year":"2020","unstructured":"Tobias PE, Varughese CA, Hanson AP, Gurnani PK. A case of linezolid induced toxicity. J Pharm Pract. 2020, 33:222-5. 10.1177\/0897190018782787","journal-title":"J Pharm Pract"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.14740\/jocmr2687w","article-title":"Lactic acidosis induced by linezolid mimics symptoms of an acute intracranial bleed: a case report and literature review","volume":"8","author":"Zuccarini NS","year":"2016","unstructured":"Zuccarini NS, Yousuf T, Wozniczka D, Rauf AA. Lactic acidosis induced by linezolid mimics symptoms of an acute intracranial bleed: a case report and literature review. J Clin Med Res. 2016, 8:753-6. 10.14740\/jocmr2687w","journal-title":"J Clin Med Res"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/j.bjid.2021.101701","article-title":"Lactic acidosis associated with standard dose linezolid in a kidney recipient with impaired renal function","volume":"26","author":"Chen CC","year":"2022","unstructured":"Chen CC, Liu WT, Lin SH. Lactic acidosis associated with standard dose linezolid in a kidney recipient with impaired renal function. Braz J Infect Dis. 2022, 26:101701. 10.1016\/j.bjid.2021.101701","journal-title":"Braz J Infect Dis"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1097\/CCM.0000000000001478","article-title":"Changes in whole-body oxygen consumption and skeletal muscle mitochondria during linezolid-induced lactic acidosis","volume":"44","author":"Protti A","year":"2016","unstructured":"Protti A, Ronchi D, Bassi G, Fortunato F, Bordoni A, Rizzuti T, Fumagalli R. Changes in whole-body oxygen consumption and skeletal muscle mitochondria during linezolid-induced lactic acidosis. Crit Care Med. 2016, 44:579-82. 10.1097\/CCM.0000000000001478","journal-title":"Crit Care Med"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1080\/08998280.2015.11929310","article-title":"A triad of linezolid toxicity: hypoglycemia, lactic acidosis, and acute pancreatitis","volume":"28","author":"Johnson PC","year":"2015","unstructured":"Johnson PC, Vaduganathan M, Phillips KM, O'Donnell WJ. A triad of linezolid toxicity: hypoglycemia, lactic acidosis, and acute pancreatitis. Proc (Bayl Univ Med Cent). 2015, 28:466-8. 10.1080\/08998280.2015.11929310","journal-title":"Proc (Bayl Univ Med Cent)"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1213\/XAA.0000000000000751","article-title":"Linezolid-induced lactic acidosis sets stage for surgery to rule out mesenteric ischemia: a case report","volume":"11","author":"Belani K","year":"2018","unstructured":"Belani K, Leibowitz A, Bose S. Linezolid-induced lactic acidosis sets stage for surgery to rule out mesenteric ischemia: a case report. A A Pract. 2018, 11:93-5. 10.1213\/XAA.0000000000000751","journal-title":"A A Pract"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1111\/nep.12346","article-title":"Severe linezolid-induced lactic acidosis in a cirrhosis patient","volume":"20","author":"Hsu SN","year":"2015","unstructured":"Hsu SN, Shih MF, Yang CW, Wu CC, Chen CC. Severe linezolid-induced lactic acidosis in a cirrhosis patient. Nephrology (Carlton). 2015, 20:47-8. 10.1111\/nep.12346","journal-title":"Nephrology (Carlton)"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1592\/phco.27.5.771","article-title":"Severe lactic acidosis associated with linezolid use in a patient with the mitochondrial DNA A2706G polymorphism","volume":"27","author":"Carson J","year":"2007","unstructured":"Carson J, Cerda J, Chae JH, Hirano M, Maggiore P. Severe lactic acidosis associated with linezolid use in a patient with the mitochondrial DNA A2706G polymorphism. Pharmacotherapy. 2007, 27:771-4. 10.1592\/phco.27.5.771","journal-title":"Pharmacotherapy"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1007\/s15010-008-7329-3","article-title":"Early linezolid-associated lactic acidosis in a patient treated for tuberculous spondylodiscitis","volume":"36","author":"Scotton P","year":"2008","unstructured":"Scotton P, Fuser R, Torresan S, et al.. Early linezolid-associated lactic acidosis in a patient treated for tuberculous spondylodiscitis. Infection. 2008, 36:387-8. 10.1007\/s15010-008-7329-3","journal-title":"Infection"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1179\/joc.2008.20.6.766","article-title":"Early development of lactic acidosis with short term linezolid treatment in a renal recipient","volume":"20","author":"Lee YR","year":"2008","unstructured":"Lee YR, Powell N, Bonatti H, et al.. Early development of lactic acidosis with short term linezolid treatment in a renal recipient. J Chemother. 2008, 20:766-7. 10.1179\/joc.2008.20.6.766","journal-title":"J Chemother"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1086\/430441","article-title":"Does linezolid cause lactic acidosis by inhibiting mitochondrial protein synthesis?","volume":"15","author":"Palenzuela L","year":"2005","unstructured":"Palenzuela L, Hahn NM, Nelson RP Jr, et al.. Does linezolid cause lactic acidosis by inhibiting mitochondrial protein synthesis?. Clin Infect Dis. 2005, 15:113-16. 10.1086\/430441","journal-title":"Clin Infect Dis"},{"key":"ref36","unstructured":"FDA. Reporting System (FAERS). Freedom of Information Act (FOIA). Detailed report: Linezolid. (2016). Accessed: May 05, 2023: https:\/\/www.fda.gov\/drugs\/questions-and-answers-fdas-adverse-event-reporting-system-faers\/fda-adverse-event-reporting."},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1086\/499533","article-title":"Hyperlactacidemia potentially due to linezolid overexposure in a liver transplant recipient","volume":"42","author":"Pea F","year":"2006","unstructured":"Pea F, Scudeller L, Lugano M, et al.. Hyperlactacidemia potentially due to linezolid overexposure in a liver transplant recipient. Clin Infect Dis. 2006, 42:434-5. 10.1086\/499533","journal-title":"Clin Infect Dis"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2016.08.023","article-title":"Therapeutic drug management of linezolid: a missed opportunity for clinicians?","volume":"48","author":"Cattaneo D","year":"2016","unstructured":"Cattaneo D, Gervasoni C, Cozzi V, Castoldi S, Baldelli S, Clementi E. Therapeutic drug management of linezolid: a missed opportunity for clinicians?. Int J Antimicrob Agents. 2016, 48:728-31. 10.1016\/j.ijantimicag.2016.08.023","journal-title":"Int J Antimicrob Agents"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2015.09.051","article-title":"Linezolid trough concentrations correlate with mitochondrial toxicity-related adverse events in the treatment of chronic extensively drug-resistant tuberculosis","volume":"9","author":"Song T","year":"2015","unstructured":"Song T, Lee M, Jeon HS, et al.. Linezolid trough concentrations correlate with mitochondrial toxicity-related adverse events in the treatment of chronic extensively drug-resistant tuberculosis. EBioMedicine. 2015, 9:1627-33. 10.1016\/j.ebiom.2015.09.051","journal-title":"EBioMedicine"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2007.04.005","article-title":"The site of action of oxazolidinone antibiotics in living bacteria and in human mitochondria","volume":"26","author":"Leach KL","year":"2007","unstructured":"Leach KL, Swaney SM, Colca JR, et al.. The site of action of oxazolidinone antibiotics in living bacteria and in human mitochondria. Mol Cell. 2007, 26:393-402. 10.1016\/j.molcel.2007.04.005","journal-title":"Mol Cell"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0804276105","article-title":"The oxazolidinone antibiotics perturb the ribosomal peptidyl-transferase center and effect tRNA positioning","volume":"9","author":"Wilson DN","year":"2008","unstructured":"Wilson DN, Schluenzen F, Harms JM, Starosta AL, Connell SR, Fucini P. The oxazolidinone antibiotics perturb the ribosomal peptidyl-transferase center and effect tRNA positioning. Proc Natl Acad Sci USA. 2008, 9:13339-44. 10.1073\/pnas.0804276105","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1021\/jm800379d","article-title":"Crystal structure of the oxazolidinone antibiotic linezolid bound to the 50S ribosomal subunit","volume":"51","author":"Ippolito JA","year":"2008","unstructured":"Ippolito JA, Kanyo ZF, Wang D, Franceschi FJ, Moore PB, Steitz TA, Duffy EM. Crystal structure of the oxazolidinone antibiotic linezolid bound to the 50S ribosomal subunit. J Med Chem. 2008, 51:3353-6. 10.1021\/jm800379d","journal-title":"J Med Chem"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1086\/501356","article-title":"Linezolid-induced inhibition of mitochondrial protein synthesis","volume":"42","author":"De Vriese AS","year":"2006","unstructured":"De Vriese AS, Coster RV, Smet J, et al.. Linezolid-induced inhibition of mitochondrial protein synthesis. Clin Infect Dis. 2006, 42:1111-17. 10.1086\/501356","journal-title":"Clin Infect Dis"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01190-06","article-title":"Reversible inhibition of mitochondrial protein synthesis during linezolid-related hyperlactatemia","volume":"51","author":"Garrabou G","year":"2007","unstructured":"Garrabou G, Soriano A, L\u00f3pez S, et al.. Reversible inhibition of mitochondrial protein synthesis during linezolid-related hyperlactatemia. Antimicrob Agents Chemother. 2007, 51:962-7. 10.1128\/AAC.01190-06","journal-title":"Antimicrob Agents Chemother"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2008.12.002","article-title":"Fatal lactic acidosis after prolonged linezolid exposure for treatment of multidrug-resistant tuberculosis","volume":"20","author":"Boutoille D","year":"2009","unstructured":"Boutoille D, Grossi O, Depatureaux A, Tattevin P. Fatal lactic acidosis after prolonged linezolid exposure for treatment of multidrug-resistant tuberculosis. Eur J Intern Med. 2009, 20:e134-5. 10.1016\/j.ejim.2008.12.002","journal-title":"Eur J Intern Med"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2014.04.032","article-title":"Linezolid-induced lactic acidosis corrected with sustained low-efficiency dialysis: a case report","volume":"64","author":"Sawyer AJ","year":"2014","unstructured":"Sawyer AJ, Haley HL, Baty SR, McGuffey GE, Eiland EH 3rd. Linezolid-induced lactic acidosis corrected with sustained low-efficiency dialysis: a case report. Am J Kidney Dis. 2014, 64:457-9. 10.1053\/j.ajkd.2014.04.032","journal-title":"Am J Kidney Dis"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1515\/cclm-2016-0438","article-title":"Lactic acidosis: an update","volume":"53","author":"Seheult J","year":"2017","unstructured":"Seheult J, Fitzpatrick G, Boran G. Lactic acidosis: an update. Clin Chem Lab Med. 2017, 53:322-33. 10.1515\/cclm-2016-0438","journal-title":"Clin Chem Lab Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/251822-linezolid-induced-lactic-acidosis-presenting-as-acute-cholecystitis-a-case-report-and-systematic-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,4]],"date-time":"2024-10-04T00:41:33Z","timestamp":1728002493000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/251822-linezolid-induced-lactic-acidosis-presenting-as-acute-cholecystitis-a-case-report-and-systematic-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,3]]},"references-count":47,"URL":"https:\/\/doi.org\/10.7759\/cureus.70794","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10,3]]}}}